AIM ImmunoTech Inc
0.0002 (0.05%)
Company Name Stock Ticker Symbol Market Type
AIM ImmunoTech Inc AIM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0002 0.05% 0.44 17:38:28
Open Price Low Price High Price Close Price Prev Close
0.425 0.41 0.4399 0.4214 0.4398
more quote information »

Recent News

Date Time Source Heading
3/16/202308:51EDGARCurrent Report Filing (8-k)
3/16/202308:45GLOBEAIM ImmunoTech Announces Late-Breaking Presentation at the..
3/13/202308:31EDGARCurrent Report Filing (8-k)
3/10/202316:06EDGARStatement of Changes in Beneficial Ownership (4)
3/08/202308:45GLOBEAIM ImmunoTech Announces Publication of New Analysis of the..
3/06/202308:45GLOBEAIM ImmunoTech Issues Letter to Stockholders
2/28/202308:45GLOBEAIM ImmunoTech Announces Phase 2 Study of Ampligen® for the..
2/17/202308:55GLOBEAIM ImmunoTech to Participate in Solve M.E. and The..
2/10/202316:41EDGARCurrent Report Filing (8-k)
2/10/202316:32EDGARAmended Securities Registration (section 12(b)) (8-a12b/a)
2/06/202307:02EDGARCurrent Report Filing (8-k)
1/17/202308:52EDGARCurrent Report Filing (8-k)
1/17/202308:45GLOBEAIM ImmunoTech Enters into Pancreatic Cancer Clinical..
1/09/202308:05GLOBEAIM ImmunoTech Broadens Patent Portfolio with New..
1/05/202308:45GLOBEAIM ImmunoTech to Present at the ‘Virtual Investor 2023..
1/04/202307:31EDGARStatement of Changes in Beneficial Ownership (4)
1/04/202307:31EDGARStatement of Changes in Beneficial Ownership (4)
1/04/202307:31EDGARStatement of Changes in Beneficial Ownership (4)
1/03/202314:59EDGARStatement of Changes in Beneficial Ownership (4)
12/12/202209:00GLOBEAIM ImmunoTech Appoints Christopher McAleer, Ph.D. as..
12/08/202208:05GLOBEAIM ImmunoTech Reports Positive Safety, Tolerability and..
12/02/202210:45GLOBEAIM ImmunoTech Announces Abstract Accepted for Poster..
11/15/202207:00GLOBEAIM ImmunoTech Reports Third Quarter 2022 Financial Results..
11/14/202217:02EDGARAmended Securities Registration (section 12(b)) (8-a12b/a)
11/14/202216:54EDGARQuarterly Report (10-q)
11/14/202207:00GLOBEAIM ImmunoTech Announces Presentation of New Data from..
11/09/202209:00BWAIM ImmunoTech Announces Corporate Governance Enhancements
11/03/202212:34BWAIM ImmunoTech Shareholders Elect All Three Company Director..
11/02/202207:05GLOBEAIM ImmunoTech Receives Orphan Drug Designation for Ampligen..
11/01/202217:19GLOBEStatement of the ASFV Committee on Ruling in Delaware Action
10/31/202208:56EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
10/31/202207:30BWDelaware Court Rules in Favor of AIM ImmunoTech and Declines..
10/26/202217:20EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
10/26/202217:12BWAIM ImmunoTech Board Issues Letter to Shareholders
10/24/202208:30GLOBEASFV Committee Reveals Troubling Statements Made by..
10/13/202216:17EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
10/13/202214:36EDGARAdditional Proxy Soliciting Materials - Non-management..
10/13/202210:32GLOBEU.S. District Court Dismisses AIM’s "Baseless" Section 13(d)..
10/12/202217:31EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
10/12/202208:45GLOBEAIM ImmunoTech Announces FDA Clearance of IND Application to..
9/28/202217:16EDGARAdditional Proxy Soliciting Materials - Non-management..
9/26/202216:16EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
9/21/202217:20EDGARRevised Proxy Soliciting Materials (definitive) (defr14a)
9/21/202208:45GLOBEAIM ImmunoTech to Present at the Virtual Investor Long COVID..
9/20/202206:06EDGARAdditional Proxy Soliciting Materials (definitive) (defa14a)
9/19/202208:05BWAIM ImmunoTech Board Files Definitive Proxy Statement and..
9/19/202208:01EDGARProxy Statment - Contested Solicitations (definitive)..
9/15/202208:52EDGARProxy Statement - Contested Solicitations (preliminary)..
9/13/202216:05EDGARInitial Statement of Beneficial Ownership (3)